Speech-Language Pathologists in Biscayne Park, FL Accepting Medicare
2 Speech-Language Pathologists found. Showing 1 - 2
 Logos Speech Therapy, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11525 Ne 8th Ave, Biscayne Park, FL 33161 Phone: 954-894-9023 Fax: 954-894-9023 |
 Ms. Nancy Proffitt Adams, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11525 Ne 8th Ave, Biscayne Park, FL 33161 Phone: 954-894-9023 Fax: 305-397-1755 |
News Archive
EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) on the new drug application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing-remitting multiple sclerosis (MS).
Patients with rheumatologic disease can safely receive life-saving cancer immunotherapy
In the largest single-center study of patients with rheumatologic diseases who were prescribed modern cancer immunotherapy with what are called immune checkpoint inhibitors, only a minority of patients experienced a flare of their rheumatologic disease or immune-related side effects.
Accenture: 58% of U.S. physicians intend to purchase EMR system within next two years
Fifty-eight percent of U.S. physicians who don't use electronic medical records (EMRs) intend to purchase an EMR system within the next two years, according to a new report from Accenture.
Study to understand how brain processes information in competitive settings
Researchers have found a way to study how our brains assess the behavior - and likely future actions - of others during competitive social interactions. Their study, described in a paper in the Proceedings of the National Academy of Sciences, is the first to use a computational approach to tease out differing patterns of brain activity during these interactions, the researchers report.
St. Jude Medical to evaluate cost-effectiveness of FFR for multivessel coronary artery disease
St. Jude Medical, Inc., a global medical device company, announced today at EuroPCR it will evaluate the incremental cost-effectiveness of Fractional Flow Reserve (FFR)-guided treatment for patients with multivessel coronary artery disease in the UK, Germany, France, Italy, Switzerland, Belgium and Canada. The analysis will also determine FFR's potential health and budget impact for each of the seven countries.
› Verified 8 days ago